Japan Agency for Medical Research and Development (AMED)The first public agency to participate in BARDA from outside the US
When GloPID-R member AMED participated in BARDA (Biomedical Advanced Research and Development Authority) Industry Day in Washington D.C. last October 15-16, it became the first public agency to take part in the event from outside the US.
At this 2-day event, a panel session was specially coordinated for AMED by BARDA, during which leading researchers participated from Japan. Among the important subjects covered in the discussions were the prospects of industry-academia partnerships with regards to Ebola vaccine development; Lassa treatment; and AMR countermeasures.
AMED believes that the fruitful discussions and sharing of information among the participants from both industry and academia will help advance the possibilities for future cooperation.
Panel discussions, breakout sessions and networking events were also on the BARDA Industry Day program with featured speakers from Rick Bright, the official representative of GloPID-R member, the US Department of Health and Human Services (Preparedness and Response); the US Food and Drug Administration, and key stakeholders from the industry sector.
BARDA is part of the US Department of Health and Human Services and was established to help protect the United States from chemical, biological, radiological, and nuclear threats, from pandemic influenza and from emerging infectious diseases.
BARDA’s support includes funding, technical assistance and core services.
